

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

MTA Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

Not applicable

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

Patient and professional submissions noted that the current disease severity criteria for biologics may lead to indirect discrimination. They reported that the Psoriasis Area and Severity Index (PASI) can underestimate disease severity in those with black or brown skin. The committee agreed to include a recommendation that when using the PASI, healthcare professionals should take into account skin colour and how this could affect the PASI score, and make any adjustments they consider appropriate.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No other equality issues were identified by the committee.
--

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the recommendations do not make it more difficult in practice for a specific group to access the technology compared with other groups.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, there is no potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, in section 4 of the appraisal consultation document.

Approved by Associate Director (name): Melinda Goodall

Date: 09/03/2017

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No, no additional potential equality issues have been raised during the consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the recommendations do not make it more difficult in practice for a specific group to access the technologies compared with other groups.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, there is no potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, in section 4.24 of the FAD and summary table.

Approved by Associate Director (name): ...Melinda Goodall.....

Date: 12/05/2017